Ahmad Ramahi1,2, Michael Hughes3,4, Dinesh Khanna1,2. 1. Division of Rheumatology, Department of Medicine. 2. University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA. 3. Tameside Hospital, Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne. 4. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK.
Abstract
PURPOSE OF REVIEW: Raynaud's phenomenon (RP) is a common vasospastic condition that results in digital hypoperfusion in response to cold and/or emotional stress and is associated with significant pain and disability. The aim of our review is to provide a practical approach for clinicians to inform assessment and management of patients with RP. RECENT FINDINGS: Autoantibodies and nailfold capillaroscopy are key investigations to stratify the risk of progression to systemic sclerosis (SSc) in patients RP, which was recently confirmed in the multicenter, very early diagnosis of systemic sclerosis (VEDOSS) project. Research has explored the complex lived-patient experience of RP including digital vasculopathy in SSc and has highlighted the need for outcome measure development to facilitate research in the field. Pharmacological treatment strategies vary significantly internationally and there is continued interest in developing surgical approaches. SUMMARY: We provide a practical and up-to-date approach to inform the assessment and management of patients with RP including guidance on drug initiation and escalation. Calcium channel blockers are first-line treatment and can be initiated by primary care physicians. We also highlight second-line drug therapies used for refractory RP and the potential role for surgical intervention.
PURPOSE OF REVIEW: Raynaud's phenomenon (RP) is a common vasospastic condition that results in digital hypoperfusion in response to cold and/or emotional stress and is associated with significant pain and disability. The aim of our review is to provide a practical approach for clinicians to inform assessment and management of patients with RP. RECENT FINDINGS: Autoantibodies and nailfold capillaroscopy are key investigations to stratify the risk of progression to systemic sclerosis (SSc) in patients RP, which was recently confirmed in the multicenter, very early diagnosis of systemic sclerosis (VEDOSS) project. Research has explored the complex lived-patient experience of RP including digital vasculopathy in SSc and has highlighted the need for outcome measure development to facilitate research in the field. Pharmacological treatment strategies vary significantly internationally and there is continued interest in developing surgical approaches. SUMMARY: We provide a practical and up-to-date approach to inform the assessment and management of patients with RP including guidance on drug initiation and escalation. Calcium channel blockers are first-line treatment and can be initiated by primary care physicians. We also highlight second-line drug therapies used for refractory RP and the potential role for surgical intervention.
Authors: Elena Schiopu; Vivien M Hsu; Ann J Impens; Jennifer A Rothman; Deborah A McCloskey; Julianne E Wilson; Kristine Phillips; James R Seibold Journal: J Rheumatol Date: 2009-09-15 Impact factor: 4.666
Authors: S Meelad Habib; Elian E A Brenninkmeijer; Maarten H Vermeer; Jeska K de Vries-Bouwstra; Peter J Velthuis Journal: Dermatol Ther Date: 2020-09-10 Impact factor: 2.851
Authors: Susan L Murphy; Alain Lescoat; Mary Alore; Michael Hughes; John D Pauling; Maya Sabbagh; Dinesh Khanna Journal: Clin Rheumatol Date: 2021-01-24 Impact factor: 2.980